Kristen Fortney - 13 Jan 2026 Form 4 Insider Report for BioAge Labs, Inc. (BIOA)

Role
Chief Executive Officer, Director
Signature
/s/ Dov A. Goldstein as attorney-in-fact
Issuer symbol
BIOA
Transactions as of
13 Jan 2026
Net transactions value
-$4,223,036
Form type
4
Filing time
15 Jan 2026, 16:20:14 UTC
Previous filing
20 Feb 2025
Next filing
19 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Fortney Kristen Chief Executive Officer, Director C/O BIOAGE LABS, INC., 5885 HOLLIS STREET, SUITE 370, EMERYVILLE /s/ Dov A. Goldstein as attorney-in-fact 15 Jan 2026 0002032751

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIOA Common Stock Sale $4,223,036 -233,107 -19% $18.12 976,949 13 Jan 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2024.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.385 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.